Retired American Burn Association President Dr. David Ahrenholz to Present on Engineered Skin Substitute (ESS) at the Vatican's Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact
Download as PDF
APRIL 25, 2016
SAN FRANCISCO, April 25, 2016 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced that Retired American Burn Association President Dr. David Ahrenholz has been selected to present Engineered Skin Substitute for the treatment of life threatening severe burns at The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact being held April 28-30, 2016 at the Vatican. Dr. Ahrenholz will be presenting on April 30, 2016 during the "Rebuilding and Restoring the Human Body" session beginning at 10:10am local time.
"I am pleased to bring to light the breakthrough ESS program that will be re-entering clinical development very shortly following an almost 6-year hiatus," said Dr. Ahrenholz. "I firmly believe that if ESS is approved by regulatory authorities, it has the potential to dramatically reduce the mortality rate and become the standard of care in the treatment of life threatening burns. For the pediatric population, not only could ESS save lives, but also significantly reduce the need for additional revision surgeries over time as patients grow - where the current standard of care requires frequent, extended-stay return to the hospital for painful additional skin grafting."
Dr. Ahrenholz previously provided a video interview on the potential of ESS for treatment of severe burns that is available online at: http://www.amarantus.com/news/videos .
Amarantus is preparing to initiate a 10-patient Phase 2 clinical trial with ESS under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas. Two additional civilian sites will be opened to accelerate enrollment of the study. A link to an article featuring the pending Phase 2 clinical trial recently featured in Military Times magazine is available at: http://www.militarytimes.com/story/military/b.../73511584/ .
ESS has already received orphan drug designation from the U.S. FDA for the treatment of severe burns covering over 50% of the body. Amarantus is planning three distinct orphan clinical development programs for ESS, all of which have the opportunity to gain rapid market approval in various dermatologic conditions:
Adult severe burns: Initiating a 10-patient Phase 2 clinical development program with US Army study under CRADA at ISR and two additional leading civilian burn centers;
Pediatric severe burns: Evaluating Phase 3 development program designs with leading pediatric burn center(s) in the United States;
Giant Congenital Melanocytic Nevi (GCMN): Evaluating pivotal development program designs with leading dermatology center(s) in the United States.
Download as PDF
APRIL 25, 2016
SAN FRANCISCO, April 25, 2016 /PRNewswire/ --
Amarantus BioScience Holdings, Inc. (OTCQX:AMBS), a biotechnology company developing products in Regenerative Medicine, Neurology and Orphan diseases, today announced that Retired American Burn Association President Dr. David Ahrenholz has been selected to present Engineered Skin Substitute for the treatment of life threatening severe burns at The Third International Conference on the Progress of Regenerative Medicine and its Cultural Impact being held April 28-30, 2016 at the Vatican. Dr. Ahrenholz will be presenting on April 30, 2016 during the "Rebuilding and Restoring the Human Body" session beginning at 10:10am local time.
"I am pleased to bring to light the breakthrough ESS program that will be re-entering clinical development very shortly following an almost 6-year hiatus," said Dr. Ahrenholz. "I firmly believe that if ESS is approved by regulatory authorities, it has the potential to dramatically reduce the mortality rate and become the standard of care in the treatment of life threatening burns. For the pediatric population, not only could ESS save lives, but also significantly reduce the need for additional revision surgeries over time as patients grow - where the current standard of care requires frequent, extended-stay return to the hospital for painful additional skin grafting."
Dr. Ahrenholz previously provided a video interview on the potential of ESS for treatment of severe burns that is available online at: http://www.amarantus.com/news/videos .
Amarantus is preparing to initiate a 10-patient Phase 2 clinical trial with ESS under a Collaborative Research & Development Agreement (CRADA) with the U.S. Army's Institute for Surgical Research (ISR) at Fort Sam Houston in Texas. Two additional civilian sites will be opened to accelerate enrollment of the study. A link to an article featuring the pending Phase 2 clinical trial recently featured in Military Times magazine is available at: http://www.militarytimes.com/story/military/b.../73511584/ .
ESS has already received orphan drug designation from the U.S. FDA for the treatment of severe burns covering over 50% of the body. Amarantus is planning three distinct orphan clinical development programs for ESS, all of which have the opportunity to gain rapid market approval in various dermatologic conditions:
Adult severe burns: Initiating a 10-patient Phase 2 clinical development program with US Army study under CRADA at ISR and two additional leading civilian burn centers;
Pediatric severe burns: Evaluating Phase 3 development program designs with leading pediatric burn center(s) in the United States;
Giant Congenital Melanocytic Nevi (GCMN): Evaluating pivotal development program designs with leading dermatology center(s) in the United States.
9
